Monitoring platelet function to reduce the risk of ischemic and bleeding complications

Area of Science:

• Cardiology
• Pharmacology
• Clinical Diagnostics

Background:

• Dual antiplatelet therapy (aspirin and a thienopyridine) is standard for acute coronary syndromes and after coronary stent implantation.
• Significant inter-individual variability exists in response to clopidogrel, a commonly prescribed thienopyridine.
• Platelet function assays can quantify this variability and detect non-responsiveness to clopidogrel.

Purpose of the Study:

• To evaluate the clinical utility of platelet function assays in patients receiving clopidogrel.
• To determine if identifying high platelet reactivity post-clopidogrel is associated with adverse cardiac events.
• To assess the requirements for adopting platelet function tests into routine clinical practice for risk stratification.

Main Methods:

• Review of studies investigating platelet function assays and their association with clinical outcomes.
• Analysis of the performance of various platelet function assays in detecting clopidogrel non-responsiveness.
• Consideration of criteria for sensitivity and specificity of assays to identify at-risk patients.

Main Results:

• Multiple studies show a correlation between high on-treatment platelet reactivity after clopidogrel administration and an increased risk of cardiac events.
• Platelet function assays demonstrate the capability to detect the wide variability in individual responses to clopidogrel.

Conclusions:

• Platelet function monitoring can identify patients at higher risk for thrombotic events despite dual antiplatelet therapy.
• Further prospective, randomized trials are needed to confirm if interventions guided by platelet function tests can improve patient outcomes.
• The role of platelet function monitoring in guiding surgical timing after antiplatelet therapy discontinuation requires additional investigation.